1997
Late sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1975
High dose intravenous bleomycin in the treatment of advanced lymphomas
Hubbard S, Chabner B, Canellos G, Young R, DeVita V. High dose intravenous bleomycin in the treatment of advanced lymphomas. European Journal Of Cancer 1975, 11: 623-626. PMID: 56271, DOI: 10.1016/0014-2964(75)90096-1.Peer-Reviewed Original ResearchConceptsFull therapeutic doseAdvanced lymphomaIntravenous bleomycinAggressive therapyProgressive lymphomaIntermittent courseConventional dosesTherapeutic doseRapid administrationDose levelsResponse ratePatientsTotal dosesHigher total dose levelsLymphomaBleomycinDosesTotal dose levelsTreatmentTherapyAdministrationDose
1973
Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man
Sponzo R, Devita V, Oliverio V. Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man. Cancer 1973, 31: 1154-1159. PMID: 4705152, DOI: 10.1002/1097-0142(197305)31:5<1154::aid-cncr2820310517>3.0.co;2-b.Peer-Reviewed Original ResearchInitial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)
Young R, Walker M, Canellos G, Schein P, Chabner B, Devita V. Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu). Cancer 1973, 31: 1164-1169. PMID: 4705154, DOI: 10.1002/1097-0142(197305)31:5<1164::aid-cncr2820310519>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsPrior therapyMultiple dosesClinical trialsCumulative marrow toxicityObjective therapeutic responseHepatic side effectsSingle oral doseReticulum cell sarcomaInitial clinical trialsPrimary brain tumorsPreliminary clinical trialsMarrow suppressionHodgkin's diseaseOral doseCell sarcomaMarrow toxicityPrimary toxicityTherapeutic responseBrain tumorsSide effectsPatientsConsiderable toxicitySubsequent courseMeCCNUDoses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply